No Data
No Data
Huaren Pharmaceutical (300110.SZ): Anhui Hengxing Pharmaceutical's hydrochloride of morphine raw material medicine has obtained the notice of application for listing approval.
On September 10th, Gelunhui reported that Huaren Pharmaceutical (300110.SZ) announced that its wholly-owned subsidiary, Anhui Hengxing Pharmaceutical Co., Ltd. (hereinafter referred to as 'Anhui Hengxing Pharmaceutical'), received the 'Approval Notice for the Marketing of Hydrochloride Papaverine Hydrochloride' chemical raw material medicine from the National Medical Products Administration (Notice No. 2024YS00938). Hydrochloride papaverine is used to treat ischemia caused by brain, heart, and peripheral vascular spasms, as well as spasms of internal organs such as kidneys, gallbladder, or gastrointestinal tract. According to statistics from Yaozhi.net, the domestic consumption of hydrochloride papaverine raw materials in 2023 was 4.
Huaren Pharmaceutical: 2024 Semi-Annual Report
Huaren Pharmaceutical: 2024 Semi-Annual Report Summary
Huaren Pharmaceutical (300110.SZ): The net income for the first half of the year was 73.213 million yuan, a 11.02% decrease compared to the same period last year.
Huaren Pharmaceutical (300110.SZ) announced its semi-annual report for 2024, with a total operating revenue of 0.771 billion yuan, a decrease of 6.95% year-on-year; net income attributable to shareholders of listed companies was 73.213 million yuan, a decrease of 11.02% year-on-year; net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was 67.8104 million yuan, a decrease of 9.29% year-on-year; basic earnings per share of 0.0619 yuan.
Huaren Pharmaceutical (300110.SZ) released its half-year performance results, with a net income of 73.213 million yuan, a decrease of 11.02%.
Huaren Pharmaceutical (300110.SZ) released the 2024 interim report, the company's revenue was 0.771 billion...
Huaren Pharmaceutical (300110.SZ): Its wholly-owned subsidiary has obtained a medical device registration certificate for the one-time use of peritoneal dialysis catheters.
On August 23rd, Huaren Pharmaceutical (300110.SZ) announced that its wholly-owned subsidiary, Qingdao Huaren Medical Supplies Co., Ltd., has received the "Peritoneal Dialysis Catheter for Single Use" Medical Instruments Registration Certificate issued by the Shandong Provincial Drug Administration. This product is used to establish a treatment pathway for patients with renal failure undergoing peritoneal dialysis.
No Data
No Data